Clinical TrialsThe Phase 2B NEST-IN1 trial for HIL-214 in norovirus failed to demonstrate effect across both primary and secondary endpoints, resulting in the discontinued development of HIL-214 in the infant population.
Product DevelopmentThe former infant study failed to meet its primary efficacy endpoint assessing moderate or severe acute gastroenteritis due to the GI.1 or GII.4 norovirus genotypes and resulted in no secondary endpoint benefit.
Restructuring CostsHLVX reported 4Q OpEx of $36.1M which was +112% vs. estimated $17M, due to $20.8M in restructuring and impairment charges.